FOR HKMA CME MEMBER USE ONLY. DO NOT REPRODUCE OR DISTRIBUTE. Influence of High Body Mass Index on Outcome in Acute Liver Failure
|
|
- Diane Ashlie Willis
- 5 years ago
- Views:
Transcription
1 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4: Influence of High Body Mass Index on Outcome in Acute Liver Failure ANNA RUTHERFORD,* TIM DAVERN, J. EILEEN HAY, NATALIE G. MURRAY, TAREK HASSANEIN, WILLIAM M. LEE, # and RAYMOND T. CHUNG* FOR THE ACUTE LIVER FAILURE STUDY GROUP *GI Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Gastroenterology, University of California San Francisco, San Francisco, California; Mayo Clinic, Rochester, Rochester, Minnesota; Baylor All Saints Transplant Services, Baylor University Medical Center, Fort Worth, Texas; University of California San Diego, San Diego, California; and # Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas Background & Aims: Diabetes and obesity affect development of nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease increases susceptibility to hepatic injury and limits regenerative capacity, which might increase adverse outcomes in acute liver failure. There is no difference in the prevalence of diabetes in acute liver failure patients when compared with the general population, but no large studies have examined the relationship of obesity to incidence or outcome of acute liver failure. Methods: Seven hundred eighty-two adult patients with acute liver failure were prospectively enrolled from Body mass index, history of diabetes, and outcome were recorded. Multivariable logistic regression was used for the analysis. Results: Compared with 30.4% of adults in the National Health and Nutrition Examination Survey III, 29.1% of adult patients with acute liver failure were obese (P.542). Obese patients had 1.63 times the odds of transplantation or death as nonobese patients ( , P.033). Severely obese patients had 1.93 times the odds of transplantation or death ( , P.042). There were no differences in the proportion of patients listed for transplantation, with body mass index greater or less than 30, 35, or 40 (P.264, P.112, P.244, respectively). Obese patients had 3.4 times the odds of dying after transplantation ( , P.01). Conclusions: Obesity does not appear to be more prevalent in acute liver failure. However, obese and severely obese patients had significantly poorer outcomes when they developed acute liver failure. This difference is not explained by weight discrimination in listing patients for transplantation, despite evidence for poorer post-transplant outcomes. There is strong evidence for the involvement of diabetes and obesity in the development of nonalcoholic fatty liver disease (NAFLD). NAFLD is a well-described feature of the metabolic syndrome that includes type II diabetes (T2DM), obesity, hypertension, and hyperlipidemia. NAFLD affects 10% 24% of the general population and 58% 75% of the obese population. Diabetes affects 7.8% of the U.S. adult population, and about 50% of patients with diabetes have NAFLD. 1 The combination of diabetes and obesity might pose an added risk; among severely obese patients with diabetes, 100% were found to have at least mild steatosis, 50% had steatohepatitis, and 19% had cirrhosis. 2 Diabetes and obesity are known to be the 2 strongest predictors of fibrosis in NAFLD. 3 There has been a considerable body of research to examine how steatosis causes liver damage. Both obese patients and patients with T2DM have increased insulin resistance. Insulin normally suppresses lipolysis; therefore, insulin resistance increases circulating levels of free fatty acids, which are taken up by the liver. Increased intrahepatic levels of fatty acids represent a potential source of oxidative stress (free electrons, H 2 O 2, and reactive oxygen species) from increased beta oxidation of fatty acids by hepatocyte mitochondria. Oxidative stress also stimulates cytokine production, which can cause hepatocyte injury and inhibit hepatic regeneration. Previous studies in animals and humans with NAFLD have shown that fatty livers are more vulnerable than normal livers to oxidative stress, sudden increases in free fatty acid supply, endotoxin/cytokine-mediated injury, and ischemia or other causes of ATP depletion. 4 Therefore, most obese diabetics have baseline evidence of underlying, clinically silent liver disease, which has been shown to be susceptible to further insults, and to have limited capacity for regeneration, 5,6 both factors that could render persons with NAFLD more susceptible to severe acute liver failure than the average population. There are 2 studies linking acute liver failure (ALF) with diabetes, not specifically related to drug toxicity. 7,8 A cohort study compared 173,643 veterans with diabetes with 650,620 controls and followed them for the occurrence of ALF during a period of 5 years. 7 After controlling for comorbid disease, age, sex, ethnicity, viral hepatitis, chronic liver disease, and alcoholism, a relative risk of 1.4 for developing ALF was observed among diabetics (P.0001). Davern et al 8 used the Acute Liver Failure Study Group (ALFSG) database to examine the prevalence of diabetes in patients with ALF, comparing this with appropriately matched controls from National Health Interview Survey (NHIS). They found that although the prevalence of diabetes was slightly higher in the ALF patients (5.3%) than in the general United States population (4.8%), the difference was not significant (P.565). There are no large studies that address the relationship between obesity and the incidence and outcome of ALF. Caldwell and Hespenheide 9 have published the only study linking obesity (body mass index [BMI] 30) with ALF. This was a retrospective description of 5 obese patients with no history of liver disease who presented with liver failure during a 4- to 16-week course and had biopsies suggestive of NAFLD. Four Abbreviations used in this paper: ALF, acute liver failure; ALFSG, Acute Liver Failure Study Group; BMI, body mass index; MELD, Model for End-stage Liver Disease; NHANES III, National Health and Nutrition Examination Survey; NHIS, National Health Interview Survey; NAFLD, nonalcoholic fatty liver disease; T2DM, type II diabetes mellitus by the AGA Institute /06/$32.00 doi: /j.cgh
2 December 2006 BMI PREDICTS POOR OUTCOME IN ALF 1545 patients died of liver failure complicated by multiorgan failure 4 16 weeks after the onset of symptoms, and one underwent successful urgent transplantation. We hypothesized that obesity is more common in patients with ALF than in appropriate control populations, and that obesity, defined as a BMI 30 kg/m 2, and/or a history of diabetes would predict poor outcome in patients with ALF. Methods The ALFSG is a National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Disease funded group of 24 academic centers established in 1998 to better define the epidemiology and outcome of ALF in the U.S. All patients enrolled into the ALFSG study have, by definition, an international normalized ratio 1.5, evidence of hepatic encephalopathy, and an illness of less than 26 weeks with no history of chronic liver disease. Because all subjects are encephalopathic, written informed consent is obtained from legal next of kin. Data are collected on separate admission and outcome case report forms, with outcome defined as liver transplantation, discharge, or death 3 weeks after admission. This study was performed according to the institutional review board guidelines of each of the 24 centers of the ALFSG and the ALFSG ancillary studies committee. Adult patients with ALF (n 782) were prospectively identified from January 1, 1998 December 31, 2004, and baseline prospective data were collected on each patient s study center, age, gender, race, height, weight, medical history of diabetes, comorbid illness, Model for End-stage Liver Disease (MELD) score, etiology of ALF, and outcome at 3 weeks after enrollment in the study. The distribution of BMIs in the ALFSG cohort was compared with a representative gender-adjusted U.S. BMI distribution estimated by the National Health and Nutrition Examination Survey (NHANES III) by using a Fisher exact test. For the analysis, the primary predictor was obesity (BMI 30 vs 30). BMI (kg/m 2 ) was calculated from weights (kg) and heights (cm) measured on admission to the study. World Health Organization criteria for BMI classification were used: underweight, 18.5; normal, ; overweight, ; obese, ; severely obese, ; very severely obese, 40. History of diabetes was defined as either mention of diabetes in medical history or at least one oral hypoglycemic medication or long-acting insulin on admission to the study. Comorbid illness was defined by using the Charlson comorbidity index. 10 MELD score was calculated by using the standard equation: (0.957 ln(creatinine mg/dl) ln(bilirubin mg/dl) ln(inr) 0.643) 10. The primary outcome for the analysis was spontaneous survival versus liver transplantation and/or death from ALF. 11,12 We examined 3-week outcomes for this study, because the initial study follow-up for the ALFSG database occurs at 3 weeks after hospitalization, transplantation, or death. In prior studies from this group, 93% of patients had a definitive outcome at 3 weeks. 13 The patients with BMI recorded in the database had their baseline characteristics compared by outcome, by using Fisher exact and Wilcoxon tests for nonparametric data. The baseline characteristics of the patients with recorded BMI were then compared with those of patients with missing BMI data by using Fisher exact and Wilcoxon tests. In crude analysis, univariate relationships were tested by using logistic regression. To determine whether obesity was related to outcome in ALF after adjusting for all other clinical variables, a multivariable logistic regression model was developed. The predictors included in the model were chosen on the basis of previously published studies of factors known to be predictive of outcome in ALF (etiology, MELD 14 ), or predictors that were significant in univariate testing. The outcomes and frequency of listing for transplant for patients with BMI 35 and 40 were examined, as well as post-transplant outcomes. All analyses were performed by using SAS for Windows version statistical software (SAS Institute Inc, Cary, NC). All analyses were 2-tailed. A P value of less than.05 was considered to indicate statistical significance. Results Patient Population Of the 782 adult patients in the ALFSG database, 573 (73.3%) had BMI recorded. Table 1 shows the baseline characteristics of these 573 patients by outcome. The mean BMI for patients who underwent transplantation or died ( kg/m 2 ) was significantly greater than that of spontaneous survivors ( kg/m 2, P.0001). Table 2 shows the baseline characteristics of the 209 missing patients as compared with the patients with BMI recorded. There were no significant differences between these 2 groups. One hundred sixty-seven (29.1%) adult ALF patients were obese, compared with 30.4% of adult Americans in the NHANES III database (P.542). 15 Table 1. Baseline Demographics of Patients by Outcome Spontaneous survival (n 255) Death and/or transplant (n 318) P value Mean age (y) % Female 65.5% (167) 66.7% (212).790 White 82.1% (206) 71.9% (220) African American 9.9% (25) 15.7% (48) Hispanic 2.4% (6) 5.2% (16).056 Asian 3.9% (10) 5.9% (18) Native American 1.6% (4) 1.3% (4) History of diabetes 5.9% (15) 6.3% (20).863 Mean BMI Charlson comorbidity score 0 78% (199) 80.5% (256) % (43) 15.4% (49) 2 5.1% (13) 4.1% (13).736 Mean MELD Etiology of ALF Acetaminophen 64.7% (165) 31.1% (99) Drug-induced liver 5.5% (14) 15.4% (49) injury Viral hepatitis 9.8% (25) 12.6% (40) Indeterminate 9.4% (24) 19.5% (62).0001 Autoimmune hepatitis 2.4% (6) 9.1% (29) Acute fatty liver of 1.2% (3) 0.3% (1) pregnancy Wilson s disease 0 3.8% (12) Other 7.1% (18) 8.2% (26)
3 1546 RUTHERFORD ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 4, No. 12 Table 2. Baseline Demographics of People With Missing BMI vs Recorded BMI Predictors of Outcome in Acute Liver Failure Table 3. Unadjusted Odds of Death and/or Transplant Predictor Missing BMI (n 209) Odds ratio BMI recorded (n 573) P value Mean age (y) % Female 71.8% (150) 66.1% (379).143 White 76.7% (158) 76.5% (426) African American 7.8% (16) 13.1% (73).057 Hispanic 7.8% (16) 4.0% (22) Asian 6.8% (14) 5.0% (28) Native American 0.9% (2) 1.4% (8) History of diabetes 4.8% (10) 6.1% (35).603 Charlson comorbidity score % (168) 79.4% (455) % (30) 16.1% (92) 2 5.3% (11) 4.5% (26) Mean MELD Etiology of ALF Acetaminophen 42.1% (88) 46.1% (264).519 Drug-induced liver injury 14.8% (31) 11.0% (63) Viral hepatitis 11.5% (24) 11.3% (65) Autoimmune hepatitis 4.3% (9) 6.1% (35) Acute fatty liver of 1.4% (3) 0.7% (4) pregnancy Wilson s disease 1.4% (3) 2.1% (12) Other 10.5% (22) 7.7% (44) Outcome Spontaneous survival 43.1% (90) 44.5% (255).745 Transplant and/or death 56.9% (119) 55.5% (318) Confidence interval P value Obesity (BMI 30) History of diabetes Age Male sex Charlson score 1 2 vs Charlson score 2 vs African American vs white Other race a vs white Study center number b.482 MELD Drug-induced vs Indeterminate vs Viral vs Other etiology c vs a Other race includes Native American, Asian, and Hispanic. b This univariate regression was done with a class statement, treating study center as a categorical variable (24 categories). The P value presented is the Wald 2 P value with 23 degrees of freedom. c Other etiology includes shock liver, mushroom toxicity, autoimmune hepatitis, Wilson s disease, acute fatty liver of pregnancy, Budd Chiari syndrome. Table 4. Adjusted Relationship of BMI to Outcome in ALF Predictor Odds ratio Confidence interval P value Obesity (BMI 30) Age Male sex Charlson score 1 2 vs Charlson score 2 vs African American vs white Other race a vs white MELD Drug-induced vs Indeterminate vs Viral vs Other etiology b vs NOTE. To describe the goodness of fit of the final model, the Hosmer- Lemeshow test for the model has a 2 value of 9.63 with P.291 with 8 degrees of freedom. a Other race includes Native American, Asian, and Hispanic. b Other etiology includes shock liver, mushroom toxicity, autoimmune hepatitis, Wilson s disease, acute fatty liver of pregnancy, Budd Chiari syndrome. The significant crude predictors of outcome in ALF include obesity, race, etiology of ALF, and MELD score (Table 3). More obese patients than nonobese patients underwent transplantation or died (67.1% and 50.7%, respectively; P.0004). On the basis of univariate analysis, an obese patient with ALF had 1.98 times the odds ( , P.0004) of undergoing transplantation or dying as compared with someone who was not obese. History of diabetes was not a significant univariate predictor of outcome. As shown in Table 4, even when adjusting for age, sex, race, history of diabetes or other comorbid illness, MELD score, and etiology of ALF, obese patients with ALF had 1.63 times the odds ( , P.033) of undergoing transplantation or dying as compared with nonobese patients. Severely obese patients (BMI 35) with ALF had 1.93 times the odds of transplantation or death ( , P.042) compared with patients with BMI 35. By separating the outcomes into death and transplantation while still controlling for age, sex, race, history of diabetes and other comorbid illness, MELD score, and etiology of ALF, obese patients with ALF had 1.35 times the odds of dying ( , P.162) and 1.58 times the odds of undergoing transplantation ( , P.055), whereas severely obese ALF patients had 1.26 times the odds of dying ( , P.414) and 1.92 times the odds of undergoing transplantation ( , P.030). Of the 19 (3.3%) ALF patients who were both obese and diabetic, 63.2% underwent transplantation or died versus 55% of the nonobese, nondiabetics (P.640). Figure 1 illustrates that as the BMI increases for patients with ALF, when compared with the patient with a normal BMI ( ), the odds of dying or undergoing transplantation significantly increases. The overall test for trend had a P value of.044. Obesity and Etiology of Acute Liver Failure Of all patients with -related ALF, obese patients were significantly under-represented compared with
4 December 2006 BMI PREDICTS POOR OUTCOME IN ALF 1547 Figure 1. Odds of death or transplantation by increasing BMI. As BMI increases for patients with ALF, when compared with the ALF patient with normal weight (BMI, ), the odds of dying or undergoing transplantation significantly increases for obese (BMI, ) and severely obese (BMI, ) ALF patients. The overall test for trend has a P value of.044. nonobese patients, when one would expect the proportion of obese patients to be similar to overall prevalence of obesity in the U.S. population (18.9% vs 81.1%, P.00001). Of all patients with autoimmune hepatitis, obese patients were significantly over-represented compared with nonobese patients (48.6% vs 51.4%, P.012). Obese patients were also significantly overrepresented in ALF caused by shock liver, mushroom toxicity, and Budd-Chiari syndrome (45.5% vs 54.6%, P.016) (Figure 2). Of all patients with BMI recorded, acute fatty liver of pregnancy occurred only in obese patients (n 4). Obesity and Liver Transplantation There was no significant difference in the proportion of patients listed for transplant with BMI greater or less than 30 (46.1% vs 40.6%, P.264), BMI greater or less than 35 (50.6% vs 40.9%, P.112), and BMI greater or less than 40 (51.3% vs 41.6%, P.244). Obese patients had 3.4 times the odds of dying after transplantation as nonobese patients ( , P.01). Discussion Several recent studies have noted associations between obesity and ALF. Canbay et al 16 retrospectively examined 34 patients with acute and acute-on-chronic liver failure. They found that BMI was significantly higher in acute-on-chronic liver failure than in ALF (P.002). Kanda et al 17 retrospectively examined 31 non-severe acute hepatitis patients, 24 severe acute hepatitis patients, and 14 fulminant hepatitis patients and found that mean BMI was not different between the non-severe and severe/fulminant groups, but that the 2 morbidly obese patients studied both developed more severe liver failure. With the benefit of the large, prospective ALFSG cohort, this study represents an opportunity to examine BMI trends in a large population with a uniform definition of ALF. Obesity was no more prevalent in this adult ALF population than in a noninstitutionalized adult U.S. population (NHANES III), implying that obesity or underlying NAFLD does not increase the risk of developing ALF itself. However, obesity was at least 60% more likely to be associated with poor outcome in ALF, specifically death or the need for liver transplantation. This relationship holds even when one controls for age, gender, and race, all of which affect the prevalence of obesity, as well as controlling for etiology of ALF, MELD score, and comorbid illness, which affect outcome. Interestingly, diabetes alone and concurrent diabetes and obesity had no further impact on patient outcome in ALF than obesity alone, suggesting that BMI is a more important predictor of outcome than diabetes. A limitation of this study is that about one fourth of the patients in the database had no BMI recorded. However as shown in Table 2, these patients were very similar to the patients with recorded BMI with respect to outcome and other clinical characteristics. The lack of BMI data recorded in this proportion of patients was likely attributable to the logistically difficult task of measuring BMI, particularly height, in critically ill patients in the intensive care unit. In fact, for the majority of patients with missing BMI, there was no height measurement recorded on the case report form. We were also unable to validate the accuracy of the measurements of height and weight in those who had BMI recorded at any study center or to distinguish whether they were estimates or actual measured values. However, we believe that weights were routinely checked in the intensive care unit setting, and heights were reasonably estimated and not subject to inherent bias. Surprisingly, the Charlson comorbidity score used to represent a patient s comorbidities was not predictive of outcome in univariate analysis. This could potentially be explained by the fact that patients with ALF tend to be quite young, and the majority had no comorbid illness (80% had a Charlson score of 0), meaning that fewer people with higher Charlson scores might have limited the power of this association. In addition, although male gender was not a significant predictor of outcome in univariate analysis, when controlling for all other factors in the multivariate model, it appeared that male gender Figure 2. BMI and etiology of ALF. Distribution of etiology of ALF differed significantly between nonobese and obese patients in ALF as a result of, autoimmune hepatitis and shock liver, mushroom toxicity, and Budd-Chiari syndrome. Of all patients with -related ALF, obese patients were significantly under-represented compared with nonobese patients, when one would expect the proportion of obese patients to be similar to overall prevalence of obesity in the U.S. population (18.9% vs 81.1%, P.00001). Of all patients with autoimmune hepatitis, obese patients were significantly over-represented compared with nonobese patients (48.6% vs 51.4%, P.012). Obese patients were also significantly over-represented in ALF caused by shock liver, mushroom toxicity, and Budd-Chiari syndrome (45.5% vs 54.6%, P.016).
5 1548 RUTHERFORD ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 4, No. 12 is almost twice as likely to predict poor outcome in ALF. In the multivariate model, gender was collinear with MELD, and there was a significant difference in the mean MELD score of men versus women ( vs , P.0001). To our knowledge, there are no prior data showing gender differences in MELD score. There were significant differences in distribution of the etiologies of ALF between obese and nonobese patients in our study. In particular, the difference in prevalence of ALF caused by between obese and nonobese patients was dramatic, despite similar survival rates in the 2 groups. Whereas these data suggest that obese patients appear to be less susceptible to ALF from, further information regarding the profile of all users would be required to reliably distinguish whether (1) obese patients are less likely to use ; or (2) they experience less hepatotoxicity for a given exposure to. In addition, an explanation for the observation that obese patients are less susceptible to ALF from is not known. One study showed that maximal plasma concentrations are reached at significantly later times and are significantly lower in obese patients compared with controls, implying a lower rate of absorption. 18 Also, animal and human studies have shown that the absolute clearance of from plasma is increased in obese subjects, a result of increased formation and clearance of glucuronide and sulfate conjugates. 19 In fact, conjugating capacity has been shown to increase proportionally to total body weight, presumably as a result of increased nutritional stores. 20 It has also been shown that obese Zucker rats possess higher total hepatic glutathione content as a result of greater liver weight. 21 Collectively, decreases in absorption and increases in conjugation and clearance of and its metabolites could explain the observed decreased frequency of ALF caused by in obese patients. We showed that obese patients with ALF had 3.4 times the odds of dying after transplantation as nonobese patients, which has been previously shown and used as evidence to limit liver transplantation in severely obese patients Interestingly, although there was no significant difference in frequency of listing patients for transplantation on the basis of different BMI, patients with BMI 30, 35, and 40 all trended toward being more frequently listed than patients with BMI below those thresholds. Although there are no uniform criteria for listing for transplantation in ALF, all centers in the ALFSG listed ALF patients if they experienced clinical worsening and had no contraindications to transplantation. Although these are not strict or measurable criteria for listing, we believe they are not inherently biased, or that the decision to list a patient is not drawn from the prognostic variables uncovered in this study. Therefore, we believe that our findings reflect not only the lack of discrimination in listing obese patients for transplantation but also the fact that obese patients with ALF tend to do more poorly and are therefore more frequently listed for transplantation. In summary, obesity does not appear to be more prevalent in ALF than in a representative sample of the U.S. noninstitutionalized, civilian population. However, obese and morbidly obese patients had significantly poorer outcomes in ALF, even when controlling for age, gender, race, comorbid illness, MELD score, and etiology of ALF. This difference is also not explained by weight discrimination in listing patients for transplantation. Diabetes did not post a significant additive risk for poor outcome for obese patients. In addition to MELD and etiology of ALF, obesity appears to be a powerful clinical marker of poor outcome in ALF, and the inclusion of BMI in future prognostic models for ALF appears to be warranted. Appendix U.S. Acute Liver Failure Study Group, : William M. Lee (Principal Investigator), Julie Polson, Linda Hynan, Joan Reisch, Carla Pezzia, Joe Webster, University of Texas Southwestern Medical Center, Dallas, Texas; Anne Larson, University of Washington, Seattle, Washington; Tim Davern, University of California, San Francisco, California; Paul Martin, Mount Sinai School of Medicine, New York, New York; Timothy Macashland, University of Nebraska, Omaha, Nebraska; J. Eileen Hay, Mayo Clinic, Rochester, Minnesota; Natalie G. Murray, Baylor University Medical Center, Dallas, Texas; Obaid Shakil Shaikh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Andres Blei, Northwestern University Medical School, Chicago, Illinois; Kenneth Ingram, Atif Zaman, Oregon Health Sciences University, Portland, Oregon; Steven Han, University of California, Los Angeles, California; Robert Fontana, University of Michigan Medical Center, Ann Arbor, Michigan; Brendan Mcguire, University of Alabama at Birmingham, Birmingham, Alabama; Raymond T. Chung, Anna Rutherford, Massachusetts General Hospital, Boston, Massachusetts; Alastair Smith, Duke University Medical, Durham, North Carolina; Michael L. Schilsky, New York Presbyterian Hospital, New York, New York; Adrian Reuben, Medical University of South Carolina; Andres Riera, Santiago Munoz, Albert Einstein Medical Center, Philadelphia, Pennsylvania; Mical Campbell, Rajender Reddy, University of Pennsylvania, Philadelphia, Pennsylvania; Todd Stravitz, Virginia Commonwealth University, Richmond, Virginia; Lorenzo Rossaro, University of California, Davis, California; Raj Satyanarayana, Mayo Clinic, Jacksonville, Jacksonville, Florida; Tarek Hassanein, University of California San Diego, San Diego, California. References 1. Gupte P, Amarapurkar D, Agal S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004; 19: Silverman JF, Pories WT, Caro JF. Liver pathology in diabetes mellitus and morbid obesity: clinical, pathological and biochemical considerations. Pathol Annu 1989;24: Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30: Day CP. NASH-related liver failure: one hit too many? Gastroenterology 2002;97: Leclercq IA, Field J, Farrell GC. Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury. Gastroenterology 2003;124: Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002;122: Davern TJ, Schilsky ML, Hynan LS, et al. Prevalence of diabetes mellitus in not increased in acute liver failure. Hepatology 2004; 40:499A. 9. Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol 2002;97:
6 December 2006 BMI PREDICTS POOR OUTCOME IN ALF Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;5: Wai CT, Fontana RJ, Polson J, et al. Clinical outcome and virologic characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat 2005;12: Schiodt F, Rossaro L, Stravitz RT, et al. Gc-globulin and prognosis in acute liver failure. Liver Transpl 2005;11: Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137: Wiesner RH. MELD/PELD and the allocation of deceased donor livers for status 1 recipients with acute fulminant hepatic failure, primary nonfunction, hepatic artery thrombosis, and acute Wilson s disease. Liver Transpl 2004;10(Suppl 2):S17 S Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents and adults, JAMA 2004;291: Canbay A, Chen SY, Gieseler RK, et al. Overweight patients are more susceptible for acute liver failure. Hepatogastroenterology 2005;65: Kanda T, Yokosuka O, Hiraide A, et al. Prevalence of obesity in patients with acute hepatitis: is severe obesity a risk factor for fulminant hepatitis in Japan? Hepatogastroeneterology 2005;52: Lee WH, Kramer WG, Granville GE. The effect of obesity on pharmacokinetics in man. J Clin Pharmacol 1981;21: Wong BK, U SW, Corcoran GB. An overfed rat model that reproduces disposition in obese humans. Drug Metab Dispos 1986;14: Abernethy DR, Greenblatt DJ, Divoll M, et al. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and. J Lab Clin Med 1983;101: Chaudhary IP, Tuntaterdtum S, McNamara PJ, et al. Effect of genetic obesity and phenobarbital treatment on the hepatic conjugation pathways. J Pharmacol Exp Ther 1993;265: Rustgi VK, Marino G, Rustgi S, et al. Impact of body mass index on graft failure and overall survival following liver transplant. Clin Transplant 2004;18: Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002;35: Pelletier SJ, Maraschio MA, Schaubel DE, et al. Survival benefit of kidney and liver transplantation for obese patients on the waiting list. Clin Transpl 2003; Address requests for reprints to: Raymond T. Chung, MD, GI Unit, GRJ 825, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts RTChung@partners.org; fax: (617) Supported by NIDDK 2 U01 DK058369, which was previously NIDDK R01 DK The authors thank the ALFSG site coordinators and nurses for their support.
Over the past 20 years, the Centers for Disease. Fulminant Hepatitis A Virus Infection in the United States: Incidence, Prognosis, and Outcomes
VIRAL HEPATITIS Fulminant Hepatitis A Virus Infection in the United States: Incidence, Prognosis, and Outcomes Ryan M. Taylor, 1 Timothy Davern, 2 Santiago Munoz, 3 Stephen-Huy Han, 4 Brendan McGuire,
More informationDrug-Induced Liver Injury and Hepatic Encephalopathy
Drug-Induced Liver Injury and Hepatic Encephalopathy William M. Lee, MD Division of Digestive and Liver Diseases UT Southwestern Medical Center at Dallas Division of Gastroenterology, Hepatology and Nutrition
More informationMeasurement of Serum Acetaminophen Protein Adducts in Patients With Acute Liver Failure
GASTROENTEROLOGY 2006;130:687 694 Measurement of Serum Acetaminophen Protein Adducts in Patients With Acute Liver Failure TIMOTHY J. DAVERN II,* LAURA P. JAMES, JACK A. HINSON, JULIE POLSON, ANNE M. LARSON,
More informationObesity is perhaps the most significant public health problem
Obesity and Its Effect on Survival in Patients Undergoing Orthotopic Liver Transplantation in the United States Satheesh Nair, 1 Sumita Verma, 2 and Paul J. Thuluvath 2 Studies assessing morbidity and
More informationFrequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States
GASTROENTEROLOGY 2011;141:1249 1253 Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States MICHAEL R. CHARLTON,* JUSTIN M. BURNS, RACHEL A. PEDERSEN, KYMBERLY
More informationWhat Is the Real Gain After Liver Transplantation?
LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom;
More informationINTERNATIONAL WORKSHOP ON MANAGEMENT OF END STAGE LIVER DISEASE DUE TO NASH WASHINGTON DC, USA 6-7 OCTOBER 2016 MEETING PROSPECTUS www.expertmedicalevents.com www.expertmedicalevents.com INTRODUCTION NAFLD
More informationThe Natural History of Severe Acute Liver Injury.
The Natural History of Severe Acute Liver Injury. David G. Koch, Medical University of South Carolina J.L. Speiser, Medical University of South Carolina V. Durkalski, Medical University of South Carolina
More informationAcute Liver Failure in the USA 2011 Evaluation of diagnostic criteria to approach DILI causality
Acute Liver Failure in the USA 2011 Evaluation of diagnostic criteria to approach DILI causality William M. Lee, MD Professor of Internal Medicine Meredith Mosle Chair in Liver Diseases UT Southwestern
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationLiver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995
Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established
More informationAmmonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis
Gastroenterology Report, 5(3), 2017, 232 236 doi: 10.1093/gastro/gow010 Advance Access Publication Date: 1 May 2016 Original article ORIGINAL ARTICLE Ammonia level at admission predicts in-hospital mortality
More informationChapter Two Incidence & prevalence
Chapter Two Incidence & prevalence Science is the observation of things possible, whether present or past. Prescience is the knowledge of things which may come to pass, though but slowly. LEONARDO da Vinci
More informationPatients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States
Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States Maria Stepanova, 1,2 Stephen Clement, 3 Robert Wong, 4 Sammy Saab,
More informationPREVALENCE OF NAFLD & NASH
- - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)
More informationLiver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals
Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer
More informationLaboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011
Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled
More informationPatients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:700 704 Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants JACQUELINE G. O LEARY, CARMEN
More informationPrevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar
Original Research Article Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Naresh Kumar 1, Jyoti Kumar Dinkar 2*, Chandrakishore
More informationAcute Liver Failure. Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018
Acute Liver Failure Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018 Disclosures None Outline Overview of ALF Management of ALF Diagnosis of ALF Treatments and Support
More informationResearch Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database
Transplantation Volume 2013, Article ID 269096, 7 pages http://dx.doi.org/10.1155/2013/269096 Research Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients:
More informationDiabetes Increases the Risk of Acute Hepatic Failure
GASTROENTEROLOGY 2002;122:1822 1828 Diabetes Increases the Risk of Acute Hepatic Failure HASHEM B. EL SERAG* and JAMES E. EVERHART *Sections of Gastroenterology and Health Services Research, Houston Department
More informationEffect of Body Mass Index on the Survival Benefit of Liver Transplantation
LIVER TRANSPLANTATION 13:1678-1683, 2007 ORIGINAL ARTICLE Effect of Body Mass Index on the Survival Benefit of Liver Transplantation Shawn J. Pelletier, 1 Douglas E. Schaubel, 2,3 Guanghui Wei, 2 Michael
More informationCurrent Concepts in Diagnosis and Management of Acute Liver Failure
Current Concepts in Diagnosis and Management of Acute Liver Failure Oren Fix, MD, MSc, FACP, AGAF, FAASLD Medical Director, Liver Transplant Program Swedish Medical Center Seattle, WA Learning Objectives
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table
More informationT he incidence of hepatocellular carcinoma (HCC) has
533 LIVER Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study J A Davila, R O Morgan, Y Shaib, K A McGlynn, H B El-Serag... See end of article
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationIn the United States, the Model for End-Stage Liver. Re-weighting the Model for End-Stage Liver Disease Score Components
GASTROENTEROLOGY 2008;135:1575 1581 Re-weighting the Model for End-Stage Liver Disease Score Components PRATIMA SHARMA,* DOUGLAS E. SCHAUBEL,, CAMELIA S. SIMA,, ROBERT M. MERION,, and ANNA S. F. LOK* *Division
More informationThe Absence of Obstructive Sleep Apnea May Protect against Non- Alcoholic Fatty Liver in Patients Undergoing Bariatric Surgery
The Absence of Obstructive Sleep Apnea May Protect against Non- Alcoholic Fatty Liver in Patients Undergoing Bariatric Surgery The Harvard community has made this article openly available. Please share
More informationNonalcoholic Fatty Liver Disease in Children: Typical and Atypical
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion
More informationNAFLD AND TYPE 2 DIABETES
NAFLD AND TYPE 2 DIABETES Sonia Caprio, MD STOPNASH Symposium on the Origin and Pathways of Nonalcoholic Steatohepatitis Washington 7, 215 Global Projection of Diabetes Hossain P et al. N Engl J Med 27;356:213
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More informationTHE MODEL FOR END-STAGE
ORIGINAL CONTRIBUTION Disparities in Liver Transplantation Before and After Introduction of the MELD Score Cynthia A. Moylan, MD Carla W. Brady, MD, MHS Jeffrey L. Johnson, MS Alastair D. Smith, MB, ChB
More informationDietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationThe pediatric end-stage liver disease (PELD) score
Selection of Pediatric Candidates Under the PELD System Sue V. McDiarmid, 1 Robert M. Merion, 2 Dawn M. Dykstra, 2 and Ann M. Harper 3 Key Points 1. The PELD score accurately predicts the 3 month probability
More informationHepatocellular carcinoma
Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More informationLiver disease is a major cause of mortality and morbidity
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:524 530 Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008 ZOBAIR M. YOUNOSSI,*, MARIA
More informationWellness Coaching for People with Prediabetes
Wellness Coaching for People with Prediabetes PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY Volume 12, E207 NOVEMBER 2015 ORIGINAL RESEARCH Wellness Coaching for People With Prediabetes: A Randomized Encouragement
More informationAmerican Journal of Oral Medicine and Radiology
American Journal of Oral Medicine and Radiology e - ISSN - XXXX-XXXX ISSN - 2394-7721 Journal homepage: www.mcmed.us/journal/ajomr PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE AMONG TYPE 2 DIABETIC POPULATION
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationNo Other Company Discloses Higher Transplant Survival Rate. Infusions For Emerging Treatments. Date of Use. Recipient Age (yrs)
Units Used In Transplants/Infusions No Other Company Discloses Higher Transplant Survival Rate Family Banking Provides Exclusive Access To Emerging Treatments With Your Own Cells 175 85% Type 1 Diabetes
More informationAnumber of studies have demonstrated a strong association
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:458 462 Reduction of Insulin Resistance With Effective Clearance of Hepatitis C Infection: Results From the HALT-C Trial AYMIN DELGADO BORREGO,* SERGIO H.
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationFATTY LIVER DISEASE (NAFLD) (NASH) A GROWING
NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams
More informationNONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat
More informationBiostats Final Project Fall 2002 Dr. Chang Claire Pothier, Michael O'Connor, Carrie Longano, Jodi Zimmerman - CSU
Biostats Final Project Fall 2002 Dr. Chang Claire Pothier, Michael O'Connor, Carrie Longano, Jodi Zimmerman - CSU Prevalence and Probability of Diabetes in Patients Referred for Stress Testing in Northeast
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries Ashwani K. Singal, MD, MS, FACG 1, Ramon Bataller, MD, PhD, FACG 2, Joseph Ahn, MD, MS, FACG (GRADE Methodologist) 3, Patrick S. Kamath,
More informationAutoimmune Hepatitis: Defining the need for Liver Transplantation
Autoimmune Hepatitis: Defining the need for Liver Transplantation Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London Outline Autoimmune Hepatitis Background
More informationGeographic Differences in Event Rates by Model for End-Stage Liver Disease Score
American Journal of Transplantation 2006; 6: 2470 2475 Blackwell Munksgaard C 2006 The Authors Journal compilation C 2006 The American Society of Transplantation and the American Society of Transplant
More informationLiver grafts for transplantation from donors with diabetes: an analysis of the Scientific Registry of Transplant Recipients database
Title Liver grafts for transplantation from donors with diabetes: an analysis of the Scientific Registry of Transplant Recipients database Author(s) Zheng, J; Xiang, J; Zhou, J; Li, Z; Hu, Z; Lo, CM; Wang,
More informationLinda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology
Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology Nonalcoholic steatohepatitis and Fatty Liver Disease Liver manifestations of the obesity epidemic Changes
More informationLiver Pathology in the 0bese
Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationCessation and Cessation Measures
Cessation and Cessation Measures among Adult Daily Smokers: National and State-Specific Data David M. Burns, Christy M. Anderson, Michael Johnson, Jacqueline M. Major, Lois Biener, Jerry Vaughn, Thomas
More informationDiabetes, Hypertension and Hyperlipidemia: Prevalence Over Time and Impact on Long-Term Survival After Liver Transplantation
American Journal of Transplantation 2012; 12: 2181 2187 Wiley Periodicals Inc. C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2012.04077.x
More informationDefining the gold standard in biomarker validation for NASH
Defining the gold standard in biomarker validation for NASH Arun J Sanyal M.D. Professor of Medicine, Physiology and Molecular Pathology Virginia Commonwealth University School of Medicine Conflicts of
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationDuring the past 2 decades, an increase in the ageadjusted
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:104 110 Racial Differences in Survival of Hepatocellular Carcinoma in the United States: A Population-Based Study JESSICA A. DAVILA* and HASHEM B. EL SERAG*,
More informationPhysician specialty and the outcomes and cost of admissions for end-stage liver disease Ko C W, Kelley K, Meyer K E
Physician specialty and the outcomes and cost of admissions for end-stage liver disease Ko C W, Kelley K, Meyer K E Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationCIRROSI E IPERTENSIONE PORTALE NELLA DONNA
Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di
More informationA study of serum ferritin as a prognostic marker in patients with decompensated liver disease
Original Research Article A study of serum ferritin as a prognostic marker in patients with decompensated liver disease P. Arul 1, S. Sangeetha 2* 1 Senior Assistant Professor, Department of General Medicine,
More informationUMHS-PUHSC JOINT INSTITUTE
Role of Visceral Adiposity in the Pathogenesis of Non-Alcoholic Fatty Liver Disease in Lean versus Obese Patients: A Comparative Study between Patients at UMHS versus PUHSC Lai WEI and Anna LOK W Zhang,
More informationQuantitative Assessment of the Liver: Breath Tests. M. Shadab Siddiqui, M.D. Virginia Commonwealth University
Quantitative Assessment of the Liver: Breath Tests M. Shadab Siddiqui, M.D. Virginia Commonwealth University Objectives Principles of breath tests Breath tests in NAFLD Potential applications of breath
More informationOrgan allocation for liver transplantation: Is MELD the answer? North American experience
Organ allocation for liver transplantation: Is MELD the answer? North American experience Douglas M. Heuman, MD Virginia Commonwealth University Richmond, VA, USA March 1998: US Department of Health and
More informationVolunteering in Oklahoma City, OK
6/17/2010 Oklahoma City Profile - Volunteering in information on volunteering and civic engagement Volunteering in Oklahoma City, OK Statistics for this area were collected within the Oklahoma City Metropolitan
More informationLiving Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?
Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department
More informationNovel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis
Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis Alina M. Allen, Meng Yin, Sudhakar K. Venkatesh, Taofic Mounajjed, Todd A. Kellogg,
More informationAssociation of Type-2 Diabetes and In-Hospital Mortality in Puerto Rican Patients Hospitalized with Decompensated Heart Failure
Association of Type-2 Diabetes and In-Hospital Mortality in Puerto Rican Patients Hospitalized with Decompensated Heart Failure Layla Cavitt, Yanel De Los Santos, Matthew Gates, Juan-Carlos Zevallos, MD,
More informationARTICLE. Prevalence of Diabetes and Impaired Fasting Glucose Levels Among US Adolescents. National Health and Nutrition Examination Survey,
ARTICLE Prevalence of Diabetes and Impaired Fasting Glucose Levels Among US Adolescents National Health and Nutrition Examination Survey, 1999-2002 Glen E. Duncan, PhD, RCEPSM Objective: To determine the
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationThe place of bariatric surgery in NASH: can we extend the indications? - No
The place of bariatric surgery in NASH: can we extend the indications? - No Nicolas Goossens Service de Gastroentérologie & Hépatologie Hôpitaux Universitaires de Genève Genève, Suisse How to extend the
More informationFatty liver disease: What do we know?
Fatty liver disease: What do we know? Prof. Dr. Claus Niederau Katholische Kliniken Oberhausen ggmbh St. Josef-Hospital Academic Teaching Hospital University of Duisburg-Essen NAFLD Non-Alcoholic Fatty
More informationon the number of organs transplanted per donor. Donor factors that affect the number of organs transplanted per donor
Donor factors that affect the number of organs transplanted per donor Background Demographic factors and factors from donors medical and social history influence the number of organs transplanted per donor.
More informationChronic liver failure affects multiple organ systems and
ORIGINAL ARTICLES Model for End-Stage Liver Disease (MELD) Predicts Nontransplant Surgical Mortality in Patients With Cirrhosis Patrick G. Northup, MD,* Ryan C. Wanamaker, MD, Vanessa D. Lee, MD, Reid
More information«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin
«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin OUTLINE NAFLD overview NAFLD and menarche NAFLD and pregnancy NAFLD and menopause Other metabolic
More informationChallenges in the Diagnosis of Steatohepatitis
The Bugaboos of Fatty Liver Disease: Ballooning and Fibrosis Hans Popper Hepatopathology Society Companion Meeting San Antonio, Tx March, 2017 David Kleiner, M.D., Ph.D. NCI/Laboratory of Pathology Challenges
More informationHCV Viremia Was Associated With Increased Mortality in a Prospective Taiwanese Cohort Study
Tram T. Tran, MD, FACG Approach to HCV Treatment in Patients with HCC Tram T. Tran, MD, FACG Professor of Medicine Medical Director, Liver Transplant Cedars Sinai Medical Center Natural History of HCV
More informationPrognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014
Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic
More informationChronic Liver Disease after Acute Hepatocellular DILI
Chronic Liver Disease after Acute Hepatocellular DILI Robert J. Fontana, MD University of Michigan Medical Center DILI Natural history of acute DILI Transplant/ death Chronic DILI Chronic DILI Incidence
More informationLife After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
More informationEarly life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.
Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem
More informationDownloaded from zjrms.ir at 3: on Monday February 25th 2019 NAFLD BMI. Kg/m2 NAFLD
logistic regression Student s t-test P< BMI BMI P< ALT AST P< Email:mkhoshbaten@yahoo.com Kg/m2 NASH RUQ B C II Case-Control II Logistic Regression Chi-Square T-test P< Grade Model 1- A diffuse hyper echoic
More informationNonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse
Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse National Institute of Diabetes and Digestive and Kidney Diseases NATIONAL INSTITUTES OF HEALTH Nonalcoholic steatohepatitis
More informationNAFLD and NASH: The Not-So-New Kids on the Block
NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an
More informationPEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE
PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based
More informationAccess and Outcomes Among Minority Transplant Patients, , with a Focus on Determinants of Kidney Graft Survival
American Journal of Transplantation 2010; 10 (Part 2): 1090 1107 Wiley Periodicals Inc. Special Feature No claim to original US government works Journal compilation C 2010 The American Society of Transplantation
More informationWhat factors determine the severity of hepatitis A-related acute liver failure?
Journal of Viral Hepatitis, 2011, 18, e167 e174 doi:10.1111/j.1365-2893.2010.01410.x What factors determine the severity of hepatitis A-related acute liver failure? V. Ajmera 1, G. Xia 2, G. Vaughan 2,
More informationNIH Public Access Author Manuscript Am J Med Sci. Author manuscript; available in PMC 2015 January 01.
NIH Public Access Author Manuscript Published in final edited form as: Am J Med Sci. 2014 January ; 347(1):. doi:10.1097/maj.0b013e31828b25a5. Association Between Metabolic Syndrome and Its Individual
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationCDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health
CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health Obesity and NAFLD Definitions: Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver
More informationSteatosi epatica ed HCV
Steatosi epatica ed HCV Malattie delle vie biliari ed Epatologia Rho, Auditorium Padri Oblati, 11 Novembre 2006 Piero L. Almasio Università di Palermo HISTOPATHOLOGY Steatosis and accelerated fibrogenesis:
More informationTrends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans
Clinical Gastroenterology and Hepatology 2016;14:301 308 Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans Fasiha Kanwal,*,, Jennifer R. Kramer,*, Zhigang Duan,*,
More information/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT
原 著 29 34-41, 2014 FIB4 Index 1 1 1 1 2 1 1 FIB4 Index FIB4 Index cut off 2.67 2.67 12,059 FIB4 IndexFIB4 Index 2.67 / FIB4 Index AST ALT FIB4 Index 2.67 161 1.3% FIB4 Index 5 FIB4 Index 1.1 5 1.6 FIB4
More information